Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-03

Study Completion Date

2016-01-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this observational study is to describe the actual conditions of prescription of micafungin in antifungal prophylaxis in French haematological and onco-haematological units. The efficacy and the safety outcomes will be described.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia

NCT02440178

Acute Leukemia

COMPLETED PHASE2

Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation

NCT01135589

Neutropenia Hematopoietic Stem Cell Transplantation Invasive Fungal Disease

UNKNOWN PHASE4

Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease

NCT02172768

Acute Graft Versus Host Disease Grade II-IV Allogeneic Stem Cell Transplant Acute Myeloid Leucaemia +1 more

COMPLETED PHASE2

Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome

NCT01200355

Acute Myelogenous Leukemia Myelodysplastic Syndrome

COMPLETED PHASE4

A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections

NCT00794703

Fungemia Fungal Infections

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Antifungal Prophylaxis Haemopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Micafungin

Patients affected with haemopathy (or affected with solid tumor for paediatric patients) under antifungal prophylaxis with micafungin.

Micafungin

Intervention Type DRUG

intravenous

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Micafungin

intravenous

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FK463 Mycamine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient with haemopathy or paediatric patients with haemopathy or solid tumor.
* Patient hospitalized in haematology, onco-haematology or onco-paediatrics unit.
* Patient initiating antifungal prophylaxis with micafungin.

Exclusion Criteria

* Patient presenting documented fungal infection.
* Patient already included in a biomedical study impacting the care management of invasive fungal infection at the time of inclusion.

Eligible Sex

ALL

Accepts Healthy Volunteers

No